To the Editor:

We read with great interest the article by Rouze and colleagues about comparing early bacterial identification between mechanically ventilated coronavirus disease (COVID-19) and influenza (1). We want to congratulate the authors for their dedication to their work. The lower COVID-19 detection rate of culture suggested that appropriate spectrum antibiotics should be chosen based on microbiological findings at the start of mechanical ventilation. However, when incorporating the results of this study into daily practice, it is necessary to solve the following knowledge gaps, in addition to the methodological issues of this study, such as standardized sampling in the prospective trial.

First, the appropriate use of antibiotics is warranted if early bacterial coinfection is suspected. However, appropriate antibiotic coverage did not modify the prognostic impact of bacterial infection in COVID-19 (1). The definition of appropriate antibiotic treatment included unnecessary use of broad-spectrum antibiotics that was reported to increase mortality (2). The finding in this study may be due to two hypotheses. First, overuse of broad-spectrum antibiotics for early bacterial infection triggers microbiome change, resulting in late-phase ventilator-associated pneumonia and influences the prognosis mediated by ventilator-associated pneumonia (3). Although it was not presented by Rouze and colleagues, investigating the effect of unnecessary initial broad-spectrum antibiotics use on the outcome might be an important future research question. Second, the local antibiotic concentration was inadequate to control the coinfection because of pulmonary macro- and/or microthrombosis (4). Thus, to determine the appropriate antibiotic strategy, both the effect of antibiotics on the prognosis and the capability of the local antimicrobial concentration to reach the effective threshold in COVID-19 should be investigated.

Although the study reported the incidence of bacterial detection, externalization of the result should be cautious for the different populations who receive different treatments. Since the initial COVID-19 pandemic, the treatment and vaccination have rapidly developed. Currently, various antiinflammatory therapies were employed in COVID-19 before intubation. Tocilizumab, for example, was associated with bloodstream infection (5). Antiinflammatory drugs mask signs of infection, making it difficult to diagnose infections in the earlier phase. The rapid distribution of the vaccine effectively addressed the issues of the pandemic. On the other hand, the new population of critically ill patients with COVID-19 will possibly be shifted from relatively healthy individuals into those who have not received the vaccine or have not acquired sufficient immunity due to their comorbidities. Rouze and colleagues reported that chronic obstructive pulmonary disease was less frequent than influenza pneumonia in patients with COVID-19, but gram-negative rods were more frequent (1). Future researchers need to address the following question: “In a world where vaccines and antiinflammatory treatments are ubiquitous, does the type of virus matter, or is the patient background more important?”

Author disclosures are available with the text of this letter at www.atljournals.org.

Daisuke Kasugai, M.D.*
Naruhiro Jingushi, M.D., Ph.D.
Norihiro Omote, M.D., Ph.D.
Yuichiro Shindo, M.D., Ph.D.
Yukari Goto, M.D.
Nagoya University Graduate School of Medicine
Nagoya, Japan

ORCID IDs: 0000-0002-8692-3003 (D.K.); 0000-0002-0207-9483 (Y.S.).

*Corresponding author (e-mail: dikasugai@med.nagoya-u.ac.jp).

References
1. Rouze A, Martin-Loeches I, Povoa P, Metzelard M, Cheyron DD, Lambiotte F, et al. coVAPid study group. Early bacterial identification among intubated patients with COVID-19 or influenza pneumonia: a European multicenter comparative cohort study. Am J Respir Crit Care Med 2021;204:546–556.
2. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Goto Y, et al.; Central Japan Lung Study Group. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect Dis 2015;15:1055–1065.
3. Rouze A, Martin-Loeches I, Povoa P, Makris D, Artigas A, Bouchereau M, et al.; coVAPid study group. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med 2021;47:188–198.
4. Wicky PH, Niedermann MS, Timsit JF. Ventilator-associated pneumonia in the era of COVID-19 pandemic: How common and what is the impact? Crit Care 2021;25:153.
5. Buetti N, Ruclky S, de Montmollin E, Reigner J, Terzi N, Cohen Y, et al. COVID-19 increased the risk of ICU-acquired bloodstream infections: a case-cohort study from the multicentric OUTCOMEREA network. Intensive Care Med 2021;47:180–187.

Copyright © 2021 by the American Thoracic Society

Reply to Kasugai et al.

From the Authors:

We thank Dr. Kasugai and colleagues for their insightful comment following our comparative cohort study (1), which raises, in
particular, the question of the futility, and even the potential harmfulness, of empirical antibiotics for suspected early bacterial coinfection among critically ill patients with coronavirus disease (COVID-19). We take this opportunity to further discuss some additional data regarding the impact of “appropriate” early antibiotic therapy on the outcome of patients with COVID-19 requiring mechanical ventilation.

Antibiotic prescribing in patients with COVID-19 is substantial. Data from first waves worldwide show a rate of antibiotic use of 75%, with antibiotics mainly being started on admission, use being significantly higher in ICU settings (up to 85%), and an increasing proportion of use being shown in mechanically ventilated patients (2). Although a trend toward reduced antibiotic use is noted as the pandemic progresses, this rate is far higher than the reported

![Kaplan-Meier 28-day survival curves for patients with coronavirus disease (COVID-19) with early bacterial identification, according to appropriateness of initial antibiotic treatment.](image)

**Figure 1.** Kaplan-Meier 28-day survival curves for patients with coronavirus disease (COVID-19) with early bacterial identification, according to appropriateness of initial antibiotic treatment.

![Kaplan-Meier 28-day survival for patients with coronavirus disease (COVID-19) without early bacterial identification, according to the presence or not of initial antibiotic treatment (within the first 24 h of ICU admission).](image)

**Figure 2.** Kaplan-Meier 28-day survival for patients with coronavirus disease (COVID-19) without early bacterial identification, according to the presence or not of initial antibiotic treatment (within the first 24 h of ICU admission).
prevalence, below 10%, of early bacterial coinfection among hospitalized patients, even in the ICU (1, 2). However, we agree with Dr. Kasugai and colleagues on the hypothesis of a future shift in the prevalence, etiology, and severity of early bacterial coinfection in patients with COVID-19 owing to the generalized use of antiinflammatory therapies and the evolution of patients’ underlying conditions, selecting those with a poor immune response to the vaccine.

Initial antibiotic therapy to treat suspected early bacterial coinfection can be retrospectively considered as “inappropriate” when 1) no antibiotic matched the in vitro susceptibility of the identified bacteria (3), and 2) no subsequent bacterial documentation occurred, leading to the conclusion of a possibly unnecessary initial antibiotic therapy. This last situation, the most frequent in daily practice, greatly depends on the effective microbiological diagnosis of coinfection. Bacterial identification may underestimate the true coinfection status owing to a lack of a quality microbiological specimen or antibiotics at the time of sampling.

Ultimately, Dr. Kasugai and colleagues address two distinct research questions. First, is appropriate early antibiotic treatment among coinfected patients with COVID-19 ineffective and, therefore, futile? As reported, only 70% of coinfected patients with COVID-19 received appropriate antibiotics. Surprisingly, although early bacterial identification was associated with an increased risk for 28-day mortality in patients with COVID-19, we did not observe an association between appropriate antibiotics and survival (28-day mortality: 42% [16/38] and 50% [8/16] in the case of appropriate and inappropriate initial antibiotic treatment, respectively; Figure 1), as one could expect (3). Interestingly, appropriate antibiotic use did not result in better survival in coinfected critically ill patients with influenza despite coinfection being an independent risk factor of death in this population (4). Second, is unnecessary initial antibiotic therapy among patients with no proven early bacterial coinfection harmful? Reducing antibiotic exposure is the cornerstone of the fight against antimicrobial resistance and nosocomial infections in the ICU (5). However, again, no association was found between antibiotics started or continued in the first 24 hours of ICU admission and mortality among patients without documented early bacterial coinfection (28-day mortality: 31% [17/54] and 27% [121/450] in the absence and presence of initial antibiotic treatment, respectively; Figure 2). However, our study was clearly underpowered to detect an effect of early antibiotics on outcome, as the number of coinfected patients with COVID-19, as well as the number of noncoinfected patients without any antibiotic upon ICU admission, was limited.

Critically ill patients with COVID-19 under mechanical ventilation may not all benefit from systematic early empirical antibiotics. Indication for antimicrobial treatment should be individualized at ICU admission after microbiological sampling, including respiratory secretions, before any antibiotic administration if possible. Toward better antimicrobial stewardship, a reasonable strategy could be to wait for the microbiological findings before prescribing antibiotics in patients with less severe disease and to initiate antibiotics with quick discontinuation based on microbiological results in patients with more severe disease, such as those with severe acute respiratory distress syndrome or septic shock.

Author disclosures are available with the text of this letter at www.atsjournals.org.

Anahita Rouzé, M.D.
Julien Labreuche, B.S.T.
Saad Nseir, M.D., Ph.D.*
CHU de Lille
Lille, France
and
Université de Lille
Lille, France

On behalf of all the authors

*Corresponding author (e-mail: s-nseir@chru-lille.fr).

References

1. Rouzé A, Martin-Loeches I, Povoa P, Metzelard M, Du Cheyron D, Lambiotte F, et al.; coVAPid study group. Early bacterial identification among intubated patients with COVID-19 or influenza pneumonia: a European multicenter comparative cohort study. Am J Respir Crit Care Med 2021;204:546–556.
2. Langford BJ, So M, Raybadharn S, Leung V, Soucy JR, Westwood D, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect 2021;27:520–531.
3. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462–474.
4. Martin-Loeches I, J Schultz M, Vincent JL, Alvarez-Lerma F, Bos LD, Solé-Violán J, et al. Increased incidence of co-infection in critically ill patients with influenza. Intensive Care Med 2017;43:45–58.
5. Rouzé A, Martin-Loeches I, Povoa P, Makris D, Artigas A, Bouchereau M, et al.; coVAPid study Group. Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. Intensive Care Med 2021;47:188–198.

Copyright © 2021 by the American Thoracic Society

Initial Triple Combination Therapy for Intermediate- and High-Risk Pulmonary Arterial Hypertension: Standard of Care or Still Too Soon to Tell?

To the Editor:

Current guidelines recommend initial oral combination therapy for patients with low- or intermediate-risk pulmonary arterial hypertension (PAH) and initial combination therapy including intravenous prostacyclin for high-risk patients, but whether dual or triple combination therapy is preferable remains an open question (1, 2). We read with great interest the perfect retrospective study from

---

8 This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org).

Originally Published in Press as DOI: 10.1164/rcrm.202107-1622E on October 21, 2021